Skip to content

Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-512544-27-00
Enrollment
54
Registered
2024-05-24
Start date
Unknown
Completion date
2025-05-16
Last updated
2024-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autosomal Dominant Polycystic Kidney Disease

Brief summary

The three primary outcomes of this study are the differences in pulse wave velocity (PWV) in high salt versus placebo group, and before versus after amiloride treatment in both groups.

Detailed description

Ambulatory (24-hours) blood pressure measurements, Serum markers of inflammation, Other relevant serum markers for inflammation and endothelial dysfunction, 23Na-MRI scans measuring interstitial sodium accumulation in a subgroup of patients, Salt tasting sensitivity

Interventions

DRUGPlacebo used in this trial is a foodgrade
DRUGredried potato starch. It is a white powder with bland taste and free from objectionable odours. Insoluble in water with a temperature below 50 °C and most organic solvents
DRUGsolution is slightly hazy. The product is intended for use in food.
DRUGSODIUM CHLORIDE
DRUGAMILORIDE

Sponsors

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The three primary outcomes of this study are the differences in pulse wave velocity (PWV) in high salt versus placebo group, and before versus after amiloride treatment in both groups.

Secondary

MeasureTime frame
Ambulatory (24-hours) blood pressure measurements, Serum markers of inflammation, Other relevant serum markers for inflammation and endothelial dysfunction, 23Na-MRI scans measuring interstitial sodium accumulation in a subgroup of patients, Salt tasting sensitivity

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026